Rheumatoid Arthritis Symptoms Reportedly Less Severe
Posted on: Friday, 2 September 2005, 09:00 CDT
FRIDAY, Sept. 2 (HealthDay News) -- Scientists have some good news for rheumatoid arthritis sufferers: The disease is becoming milder, with less severe symptoms and less functional disability compared to that experienced by arthritis patients in the past.
The exact reasons for the decline in rheumatoid arthritis severity remains unclear, Dutch researchers say, but may stem from the more aggressive drug therapies that are now available to patients.
Reporting in the September issue of Arthritis & Rheumatism, researchers reviewed the cases of rheumatoid arthritis sufferers treated by the Radboud University Nijmegen Medical Centre since 1985.
"Patients with early rheumatoid arthritis presenting in recent years have less severe disease activity at presentation, as well as a more favorable course of their disease, compared with patients in earlier years," lead researcher Paco Welsing said in a prepared statement.
His team found a correlation between more aggressive treatment strategies and less severe symptoms among more recent groups of patients. These included the use of early treatment with the drugs methotrexate or prednisone to manage both the symptoms and destructive progression of arthritis.
More information
The National Institutes of Health has more about rheumatoid arthritis.
SOURCE: John Wiley & Sons Inc., news release, Sept. 2, 2005~RHAR~~AGNG~~BONE~~PAIN~
Source: HealthSCOUT
Related Articles
- New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives
- New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
- Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
- New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients With Recent Disease Onset or Long-Standing Disease
- Can-Fite Presents Results Showing a Correlation Between High Expression of the Receptor Target for Its Drug CF101 and Rheumatoid Arthritis Patients' Response to the Drug
- Can-Fite Initiated Phase IIb Clinical Trials in Rheumatoid Arthritis Patients; Has Achieved Milestones Enabling It to Convert Issued Debentures
- Elan and Biogen Idec Announce TYSABRI(R) Safety Evaluation Findings in Crohn's Disease and Rheumatoid Arthritis Patients; TYSABRI Safety Evaluation Complete; No New Confirmed Cases of PML
- Abbott's HUMIRA(R) (Adalimumab) Shown to Improve Quality of Life for Psoriatic Arthritis Patients
- Isis Pharmaceuticals Announces Results of Alicaforsen Phase 3 Clinical Trials in Patients With Crohn's Disease
- Pediatric Crohn's Disease and Growth Retardation: The Role of Genotype, Phenotype, and Disease Severity
 |
 |
User Comments (0)
RSS Feeds